Pharmaceutical Technology

MAY 11, 2023

Bayer has entered a strategic collaboration agreement with biotechnology company Bicycle Therapeutics to discover, develop, manufacture and commercialise Bicycle’s radioconjugates for a number of oncology targets. Bicyclic peptides feature amino acids that can be manufactured synthetically.

Development 162

Development Manufacturing Protein Clinical Development 162

Outsourcing Pharma

SEPTEMBER 22, 2022

Epicâs Life Sciences program is released with the aim to connect providers, pharmaceutical companies, and medical device manufacturers to recruit research participants, expand clinical trial access, and to speed up therapy development.

Clinical Research 52

Clinical Research Life Science Research Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

We continue to make meaningful progress as we work to test, manufacture and ultimately deliver NVX-CoV2373 with unprecedented speed, as well as put partnerships in place that would ensure widespread and equitable access worldwide.”. and Mexico pivotal Phase 3 trial and manufacturing scale-up. . Mexico pivotal Phase 3 trial update.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. CARLSBAD, Calif. , Thermo Fisher Scientific Inc.

Manufacturing 52

Manufacturing Life Science Development Research 52

Camargo

JULY 30, 2021

Barry Mangum talks the importance of pediatric research, its evolution over the years, and the obstacles and opportunities that the industry faces as it moves forward. How long have you been in pediatric clinical research, and how did you enter the field? So I’ve been working in that space about 43 years.

Clinical Research 226

Clinical Research Research Gene Therapy Gene 226

pharmaphorum

APRIL 19, 2021

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . If you look at the development, we signed 15,000 people in six weeks in a trial set up by the NHS.

Vaccination 141

Vaccination Vaccine Manufacturing Clinical Development 141

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About BioInvent.

Antibody 52

Antibody Manufacturing Clinical Trials Clinical Trials 52

BioPharma Reporter

OCTOBER 11, 2022

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

Clinical Development 52

Clinical Development Manufacturing Development Research 52

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

JUNE 13, 2023

Neobiosis chief scientific officer and CEO Dr Ian White stated: “This is an important milestone for Neobiosis and we are excited to be advancing ViXome, a refined product extracted from thoroughly screened and sterile amniotic fluid obtained at the time of C-section [Caesarean delivery] of full-term pregnancies, into clinical development. “We

FDA Approval 147

FDA Approval Production Clinical Development Manufacturing 147

pharmaphorum

SEPTEMBER 29, 2020

Such collaborations take on many forms, ranging from early, multi-party alliances and consortia – which are often pre-competitive in nature – driving the development and shared learnings from technologies that may be enabling the field as a whole, through to more bespoke collaborations between entities.

Research 132

Research Gene Editing Gene Development 132

The Pharma Data

SEPTEMBER 22, 2020

Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This guidance provides clarity on the path to registration for AVXS-101 IT.

Clinical Development 52

Clinical Development Gene Therapy Development Gene 52

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). Astellas will also receive specific rights linked to any possible change of Taysha’s control.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Drug Discovery World

MAY 11, 2023

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. billion.

Manufacturing 97

Manufacturing Protein Clinical Development Development 97

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus. It operates in New Zealand, Fiji and the US.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). It was also under development for the treatment of cervical intraepithelial neoplasia caused by human papilloma virus. It operates in New Zealand, Fiji and the US.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. It was under development for the treatment of small-cell lung cancer, cholangiocarcinoma, small-cell lung cancer, urothelial cell cancer and endometrial cancer.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1.

Clinical Development 52

Clinical Development Medicine Development Containment 52

BioPharma Reporter

NOVEMBER 3, 2022

Purdue University and the pharma company will create a scholarship program and renew their strategic research collaboration as part of the agreement.

Manufacturing 52

Manufacturing Pharma Companies Research Clinical Development 52

The Pharma Data

JANUARY 17, 2021

18, 2021 /PRNewswire/ — Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Lonza announced today their agreement in support of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). NEW YORK , Jan.

Manufacturing 52

Manufacturing Gene Therapy Trials Gene 52

BioTech 365

SEPTEMBER 18, 2020

million 100% funding for development, manufacturing and commercial registration of Ii-Key- … Continue reading →

Licensing 40

Licensing Licensing Clinical Development Development 40

Pharmaceutical Technology

DECEMBER 6, 2022

Using ExpreS 2 ion’s ExpreS2 platform, the company will manufacture the antigen constructs obtained from RAVEN. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Clinical Trial Podcast

SEPTEMBER 26, 2022

To answer these two questions, regulatory authorities around the world require medical product manufacturers to conduct Phase I, also known as early phase clinical trials. Cohen has more than 30 years of healthcare experience which includes his work on clinical development. And will this interaction be safe?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Clinical Research 98

Pharmaceutical Technology

AUGUST 17, 2022

The latest development comes after the company and Cerevance signed a multi-year strategic research collaboration to discover new targets for Alzheimer’s disease. In addition, Merck will make a $100m equity investment in Orna’s Series B funding round concluded recently.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Camargo

DECEMBER 20, 2021

A key provision of PDUFA VII is a budget and staffing increase for the Center for Biologics Evaluation and Research (CBER). Notably, these new additions to CBER’s staff will far outnumber the 123 new hires budgeted for the Center for Drugs Evaluation and Research (CDER) over the same period. Beefing Up CBER. 2024: 48 staffers.

Gene Therapy 184

Gene Therapy Gene Development Production 184

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. Jiangsu Hengrui Medicine overview Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products. It is a hydroxamate.

Production 100

Production Manufacturing Drugs Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products.

Production 100

Production Manufacturing Drugs Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Italfarmaco overview Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company that develops, manufactures, commercializes and licences medicinal products. It is a hydroxamate.

Production 100

Production Manufacturing Drugs Development 100

Pharmaceutical Technology

JULY 7, 2022

A new frontier in cancer research. Cell and gene therapies are currently at the forefront of immunotherapy cancer research, and a few approved therapies are already making a difference to disease outcomes for patients. Using a similar treatment to target solid tumours could be the industry’s next major milestone.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

XTalks

JUNE 23, 2022

Jason Bock is a biopharma industry veteran who helped build the Biologics Development team that was formerly part of the Therapeutics Discovery division at the University of Texas MD Anderson Cancer Center. Dr. Bock is currently the CEO of the Cell Therapy Manufacturing Center at the Texas Medical Center.

Manufacturing 98

Manufacturing Development Engineer Clinical Development 98

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. It was also under development for the treatment of idiopathic/primary membranous nephropathy. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. It was also under development for the treatment of idiopathic/primary membranous nephropathy. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Drug Discovery World

JANUARY 5, 2023

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School. . It also exhibited much less liver toxicity when administered intravenously. .

Gene Therapy 52

Gene Therapy Gene Manufacturing Clinical Development 52

Drug Discovery World

APRIL 17, 2024

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialisation of ARV-766 and will have all research, development, manufacturing, and commercialisation rights with respect to the preclinical AR-V7 programme.

Protein 52

Protein Licensing Licensing Sales 52